F. Tas Et Al. , "Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, pp.631-637, 2014
Tas, F. Et Al. 2014. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3 , 631-637.
Tas, F., Karabulut, S., Serilmez, M., Ciftci, R., & Duranyildiz, D., (2014). Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, 631-637.
Tas, Faruk Et Al. "Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, 631-637, 2014
Tas, Faruk Et Al. "Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, pp.631-637, 2014
Tas, F. Et Al. (2014) . "Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.3, pp.631-637.
@article{article, author={Faruk TAŞ Et Al. }, title={Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2014, pages={631-637} }